Press Release: Soliris : Soliris® (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion announced that the MHLW in Japan has approved Soliris as a treatment for patients with gMG who are anti-AChR anti-body positive.
Read full article »
CEO
Soliris's headquarters is located in New Haven, Connecticut. Soliris generates $1M in revenue per employee Soliris has 1 followers on Owler.